Jan Robison
biostrategy
BSc in Biotechnology, learning finance while traveling Investor's Biker’s style, without the bike.
Recent Articles by Jan Robison
Dec 9, 2013
by Jan Robison
Orexigen Therapeutics: Light at the End of the Tunnel?
Orexigen Therapeutics announces successful interim results for its lead product candidate Contrave followed by the potentially share dilutive announcement of $100 million convertible senior notes offering. Which way should the stock go?
Nov 20, 2013
by Jan Robison
Celgene's Product Portfolio Performance Boosts Valuation Prospects
Celgene, which has almost doubled in value since the begining of the year, reported a strong 3rd quarter performance, raised its EPS guidance for the year and is poised for another exceptional year in 2014.
Nov 11, 2013
by Jan Robison
Seattle Genetics Is Down but Not Out
Seattle Genetics share price has been trending lower lately due to adverse side effects experienced by some patients undergoing clinical trials with the company’s lead product Adcetris. Since long term prospects look bright forSeattle, this could be a nice chance for value investors to enter the stock.
HOW THE MOTLEY FOOL CAN HELP YOU
-
Premium Investing Guidance
Market beating stocks from our award-winning service
-
The Daily Upside Newsletter
Investment news and high-quality insights delivered straight to your inbox
-
Get Started Investing
You can do it. Successful investing in just a few steps
-
Win at Retirement
Secrets and strategies for the post-work life you want.
-
Find a Broker
Find the right brokerage account for you.
-
Listen to our Podcasts
Hear our experts take on stocks, the market, and how to invest.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.